Before we get into the gist of today’s post let’s get some numbers out of the way as the results released by Lilly today were pretty damn good. As expected, sales of Trulicity, Jardiance and Basaglar continue to accelerate while sales of Humalog continue to struggle due to continued pricing pressure, nothing new and/or unexpected.

The company should also be congratulated for the approval of Baqsimi the first nasally administered glucagon to treat severe hypoglycemia. Although we don’t expect Baqsimi to have a material impact on revenues it’s an innovative product which will help patients . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.